Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
No 8-K events recorded for this window.
Revenue grew 5.8% to $3.5 billion with adjusted EPS of $4.25, up 10.6%, as specialty testing in neurology and oncology drove double-digit growth. The consumer health platform and AI-powered diagnostics launches expanded the addressable market while the CHOP collaboration was signed. Management raised full-year EPS guidance to $17.70-$18.35, upgrading the growth rate to approximately 10%.
Demand | Regulation Policy | Margin | Innovation & R&D | M&A | Pricing | Revenue Growth | Cost Pressure | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 3 | 3 | 4 | 3 | 2 | 1 | 2 |
| 2025Q1 | 10 | 3 | 3 | 3 | 2 | 1 | 3 | |
| 2025Q2 | 9 | 2 | 3 | 2 | 2 | 2 | 3 | |
| 2025Q3 | 7 | 3 | 3 | 2 | 3 | 1 | 3 | 2 |
| 2025Q4 | 11 | 3 | 3 | 4 | 2 | 2 | 1 | |
| 2026Q1 | 6 | 4 | 1 | 2 | 1 | 1 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 10 | 9 | 7 | 11 | 6 |
| Regulation Policy | 3 | 3 | 2 | 3 | 3 | 4 |
| Margin | 3 | 3 | 3 | 3 | 3 | 1 |
| Innovation & R&D | 4 | 2 | 2 | 4 | 2 | |
| M&A | 3 | 3 | 2 | 3 | 2 | 1 |
| Pricing | 2 | 2 | 2 | 1 | 2 | 1 |
| Revenue Growth | 1 | 1 | 3 | 3 | 1 | 1 |
| Cost Pressure | 2 | 3 | 2 | 1 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.33B | +9.8% | $1.70 | +186.3% | 26.9% | 6.5% | 4.3% | $665M |
| FY2025 Q1 | $3.35B | +5.3% | $2.52 | -6.3% | 28.3% | 9.7% | 6.4% | $-108M |
| FY2025 Q2 | $3.53B | +9.5% | $2.84 | +16.4% | 29.7% | 11.2% | 6.7% | $543M |
| FY2025 Q3 | $3.56B | +8.6% | $3.12 | +55.2% | 28.8% | 11.1% | 7.3% | $281M |
| FY2025 Q4 | $3.52B | +5.6% | $1.98 | +16.5% | 26.2% | 10.9% | 4.7% | $490M |
| FY2026 Q1Selected | $3.54B | +5.8% | $3.35 | +32.9% | 26.5% | 10.8% | 7.9% | $71M |
| FY2026 Q2 | $3.73B | +5.8% | $3.64 | +28.2% | 31.8% | 11.9% | 8.0% | $314M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call Apr 30, 2026
FY2026 Q1 in brief
Revenue grew 5.8% to $3.5 billion with adjusted EPS of $4.25, up 10.6%, as specialty testing in neurology and oncology drove double-digit growth.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +5.75% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for LabCorp (LH), FY2026 Q1: 8/10. Scores: LabCorp’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: LH daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Jack Meehan | Operon Research | 10 questions · 10% challenging |
| Erin Wright | Morgan Stanley | 10 questions · 0% challenging |
| Lisa Gill | JPMorgan | 8 questions · 0% challenging |
| Mike Ryskin | Bank of America | 7 questions · 0% challenging |
| Kevin Caliendo | UBS | 7 questions · 14% challenging |
| Mike Cherny | Leerink Partners | 7 questions · 0% challenging |
| Tycho Peterson | Jefferies | 6 questions · 0% challenging |
| Patrick Donnelly | Citigroup | 6 questions · 0% challenging |
| Pito Chickering | Deutsche Bank | 5 questions · 0% challenging |
| Elizabeth Anderson | Evercore ISI | 5 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Operon Research | 1 analyst | 10 questions · 10% challenging |
| Morgan Stanley | 1 analyst | 10 questions · 0% challenging |
| Leerink Partners | 2 analysts | 9 questions · 0% challenging |
| JPMorgan | 1 analyst | 8 questions · 0% challenging |
| Bank of America | 1 analyst | 7 questions · 0% challenging |
| Evercore ISI | 2 analysts | 7 questions · 14% challenging |
| UBS | 1 analyst | 7 questions · 14% challenging |
| Deutsche Bank | 2 analysts | 6 questions · 0% challenging |
What LH and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“And Optum AI, our new AI consulting arm, has already signed its first few contracts, helping companies like LabCorp through their operational AI initiatives.”
UNH's Optum AI consulting arm named LabCorp as an early client for operational AI initiatives.
“We recently announced a nationwide strategic collaboration with Children's Hospital of Philadelphia to expand access to cutting-edge diagnostics for pediatric patients.”
Labcorp announced a nationwide diagnostics collaboration with Children's Hospital of Philadelphia.
“And then Alzheimer's, I know you did the Roche deal for the primary care market.”
Analyst references a Labcorp-Roche deal for Alzheimer's testing in the primary care market.
“an expansion of our collaboration with PathAI to deploy an FDA-cleared digital pathology platform across our national anatomic pathology labs and hospital laboratory collaboration.”
Labcorp expanded its PathAI collaboration to deploy an FDA-cleared digital pathology platform across its labs.
“As part of our growth in specialty areas, we're collaborating with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings.”
Labcorp is collaborating with Illumina to broaden genomic-testing access in oncology, a channel signal for Illumina.
“A strategic collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency and enhance the patient and provider experience, providing clear insights to patients about their health, test progress and next steps in care.”
Labcorp expanded its long-standing collaboration with UnitedHealth's Optum to apply AI to lab operations.
“A new AI-powered real-world data platform being developed in partnership with Amazon Web Services and Datavant to accelerate Alzheimer's research.”
Datavant is a data-platform partner on Labcorp's Alzheimer's real-world-data initiative.
“A new AI-powered real-world data platform being developed in partnership with Amazon Web Services and Datavant to accelerate Alzheimer's research.”
Labcorp is partnering with AWS on an AI real-world-data platform for Alzheimer's research, an enterprise-AI win for Amazon's cloud arm.
“We expanded nationwide access to the first FDA-approved companion diagnostics that helps identify platinum-resistant ovarian cancer patients who may benefit from Merck's KEYTRUDA, which can reduce the risk of disease progression and improve overall survival.”
Labcorp launched the first FDA-approved companion diagnostic tied to Merck's KEYTRUDA for platinum-resistant ovarian cancer, a demand signal for the drug.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
LH LabCorp | 8 | +5.8% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| ILMN Illumina, Inc. | 8 | +4.8% | |
| IQV IQVIA | 7 | +8.4% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |